GoodRx Holdings, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Class A and Class BCommon Stock · AdditionalPaid-in Capital · Accumulated Deficit · TotalStockholders' Equity | |||||
|---|---|---|---|---|---|
| (in thousands) · Shares · Amount | |||||
| Balance at December 31, 2022 | 397,025 | $40 | $2,263,322 | $(1,448,535) | $814,827 |
| Stock options exercised | 1,828 | — | 6,288 | — | 6,288 |
| Stock-based compensation | — | — | 117,964 | — | 117,964 |
| Vesting and settlement of restricted stock units | 25,008 | 3 | — | — | 3 |
| Common stock withheld related to net share settlement | (11,661) | (1) | (65,671) | — | (65,672) |
| Repurchases of Class A common stock (1) | (18,433) | (2) | (103,972) | — | (103,974) |
| Issuance of common stock through employee stock purchase plan | 320 | — | 1,390 | — | 1,390 |
| Net loss | — | — | — | (8,868) | (8,868) |
| Balance at December 31, 2023 | 394,087 | $40 | $2,219,321 | $(1,457,403) | $761,958 |
| Stock options exercised | 3,287 | — | 18,887 | — | 18,887 |
| Stock-based compensation | — | — | 115,150 | — | 115,150 |
| Vesting and settlement of restricted stock units | 11,452 | — | — | — | — |
| Common stock withheld related to net share settlement | (4,336) | — | (29,789) | — | (29,789) |
| Repurchases of Class A common stock (1) | (22,085) | (2) | (159,702) | — | (159,704) |
| Issuance of common stock through employee stock purchase plan | 410 | — | 1,766 | — | 1,766 |
| Net income | — | — | — | 16,390 | 16,390 |
| Balance at December 31, 2024 | 382,815 | $38 | $2,165,633 | $(1,441,013) | $724,658 |
| Stock options exercised | 41 | — | 61 | — | 61 |
| Stock-based compensation | — | — | 91,700 | — | 91,700 |
| Vesting and settlement of restricted stock units | 10,264 | — | — | — | — |
| Common stock withheld related to net share settlement | (3,632) | — | (14,467) | — | (14,467) |
| Repurchases of Class A common stock (1) | (48,853) | (4) | (217,433) | — | (217,437) |
| Issuance of common stock through employee stock purchase plan | 417 | — | 1,308 | — | 1,308 |
| Net income | — | — | — | 30,439 | 30,439 |
| Balance at December 31, 2025 | 341,052 | $34 | $2,026,802 | $(1,410,574) | $616,262 |
(1)Repurchases of Class A common stock for the years ended December 31, 2025,2024, and 2023 include 20.0 million,20.9 million, and 12.0 million shares
repurchased from related parties (after giving effect to the automatic conversion of Class B common stock to Class A common stock upon such repurchase) for
an aggregate consideration of$84.9 million,$151.4 million, and$65.9 million, respectively. See "Note 14. Stockholders' Equity" for additional information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.